STOCK TITAN

Aeterna Zentaris Inc. - $AEZS STOCK NEWS

Welcome to our dedicated page for Aeterna Zentaris news (Ticker: $AEZS), a resource for investors and traders seeking the latest updates and insights on Aeterna Zentaris stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aeterna Zentaris's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aeterna Zentaris's position in the market.

Rhea-AI Summary

Aeterna Zentaris has finalized details of its merger with Ceapro. On May 3, 2024, Aeterna completed a 1-for-4 reverse stock split. Ceapro shareholders will receive 0.02360 of a post-split Aeterna share for each Ceapro share held. Aeterna shareholders on record by May 29, 2024, will get 0.47698 of a warrant per share on May 31, 2024. These shares will trade with a due bill from May 29 to May 31, 2024, ensuring buyers receive warrants. Ex-distribution trading starts on June 3, 2024. The due bill redemption is on June 4, 2024. Shareholders need to take no action to receive warrants, which will be managed electronically. The merger is expected to close on or about June 3, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
Rhea-AI Summary

Aeterna Zentaris (NASDAQ: AEZS) reported its Q1 2024 financial results, highlighting a cash position of $29.5 million as of March 31, 2024. The company reported a net loss of $5.8 million, compared to a $4.3 million loss in Q1 2023. This increased loss is attributed to a $2.1 million revenue drop and a $1.2 million rise in selling, general, and administrative expenses, mostly due to merger-related costs. The company successfully completed recruitment for its DETECT-trial, with results expected in Q3 2024. The merger with Ceapro Inc. is anticipated to close in Q2 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
-
Rhea-AI Summary

Aeterna Zentaris Inc. announces the effective date of the share consolidation, reducing the number of common shares by merging with Ceapro Inc. The consolidation will result in one post-consolidation common share for every four pre-consolidation common shares. The company's transfer agent will provide instructions for shareholders on trading post-consolidation common shares on the TSX and Nasdaq Capital Market on May 3, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.18%
Tags
none
Rhea-AI Summary
Aeterna Zentaris Inc. and Ceapro Inc. have received final court approval for their all-stock merger of equals transaction. The Transaction is expected to be completed in the second quarter of 2024, pending necessary approvals and conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
-
Rhea-AI Summary
Aeterna Zentaris Inc. completes enrollment in pivotal Phase 3 trial, reports $34.0 million cash, and announces merger with Ceapro, Inc. Financial results show a net loss decrease in Q4 2023 compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
-
Rhea-AI Summary
Aeterna Zentaris Inc. and Ceapro Inc. announce the approval of their all-stock merger of equals transaction by securityholders. The voting results show strong support for the merger, with Aeterna shareholders approving the transaction by high percentages. The merger is expected to create a sustainable business for delivering value to the biopharma sector and shareholders. The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.51%
Tags
Rhea-AI Summary
Aeterna Zentaris Inc. recommends shareholders vote for the merger with Ceapro Inc. to create a diversified biopharmaceutical company. The merger aims to combine Ceapro's revenue-generating cosmeceutical business with Aeterna's pipeline of higher-margin pharmaceutical products, potentially leading to stable cash flow, diversified product pipeline, and expanded R&D capabilities. The merger is expected to provide a compelling value proposition and lower risk profile for the combined company and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
-
Rhea-AI Summary
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) have announced a definitive agreement to combine operations in an all-stock merger of equals transaction. The combined company is expected to be listed on the Nasdaq Capital Market and the Toronto Stock Exchange, creating a long-term sustainable business optimally positioned to deliver value as the biopharma sector recovers. Shareholders of each company will share in future value creation, with existing securityholders of Aeterna and Ceapro to each own 50% of the combined company, respectively. The transaction is expected to close in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
-
Rhea-AI Summary
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) reported the launch of Ghryvelin™ in key European countries, approval of Macrilen® in South Korea, and ended the quarter with $38.8 million in cash, projecting funding into 2025. The company's financial results for the quarter ended September 30, 2023, show a net loss of $4.1 million and a revenue decrease of $1.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
Rhea-AI Summary
Aeterna Zentaris Inc. announced that its CEO, Dr. Klaus Paulini, will participate in the Virtual Investor Ask the CEO Conference on October 25th. Investors can submit questions live or pre-submit them through the event's website. The presentation will be available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
conferences
Aeterna Zentaris Inc.

Nasdaq:AEZS

AEZS Rankings

AEZS Stock Data

10.16M
4.85M
3.95%
0.8%
0.45%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Summerville

About AEZS

æterna zentaris inc. (tsx: aez, nasdaq: aezs) is a global biopharmaceutical company focused on endrocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. æterna zentaris inc. (tsx: aez, nasdaq: aezs) est une société biopharmaceutique internationale, spécialisée dans la découverte, le développement et la commercialisation de thérapies en endocrinologie et en oncologie.